Anzeige
Mehr »
Login
Donnerstag, 24.04.2025 Börsentäglich über 12.000 News von 692 internationalen Medien
Jetzt knallt's an der Börse! Diese Aktie hat das Zeug zum Überflieger!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QD61 | ISIN: US82024L1035 | Ticker-Symbol:
NASDAQ
23.04.25
21:17 Uhr
0,820 US-Dollar
0,000
0,00 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
SHATTUCK LABS INC Chart 1 Jahr
5-Tage-Chart
SHATTUCK LABS INC 5-Tage-Chart

Aktuelle News zur SHATTUCK LABS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
02.04.Shattuck Labs GAAP EPS of -$0.371
28.03.H.C. Wainwright holds Shattuck Labs stock at Neutral2
27.03.Shattuck Labs, Inc Loss At -$18.68 Mln In Q41
27.03.Shattuck Labs, Inc. - S-8, Securities to be offered to employees in employee benefit plans1
SHATTUCK LABS Aktie jetzt für 0€ handeln
27.03.Shattuck Labs, Inc. - 10-K, Annual Report1
27.03.Shattuck Labs, Inc.: Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights352- Presented preclinical non-human primate (NHP) data at the 20th Congress of European Crohn's and Colitis Organization in Inflammatory Bowel Diseases 2025 (ECCO) for SL-325, a potentially first-in-class...
► Artikel lesen
27.03.Shattuck Labs, Inc. - 8-K, Current Report-
17.03.Leerink initiates Shattuck Labs stock with Outperform, $4 target2
20.02.Shattuck Labs berichtet über positive präklinische Daten für SL-3252
13.02.Shattuck Labs, Inc.: Shattuck Labs Announces Oral Presentation at Upcoming 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 20252
04.02.Shattuck Labs, Inc.: Shattuck Labs Announces Poster Presentation at Upcoming 2025 Crohn's and Colitis Congress2
02.01.Shattuck Labs gears up for DR3 antagonist trials in 20252
02.01.Shattuck Labs, Inc.: Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2025115AUSTIN, TX and DURHAM, NC, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor...
► Artikel lesen
14.11.24Shattuck Labs GAAP EPS of -$0.33 beats by $0.06, revenue of $3M1
14.11.24Shattuck Labs, Inc. - 10-Q, Quarterly Report-
14.11.24Shattuck Labs, Inc. - 8-K, Current Report-
01.10.24Pre-market Movers: Shattuck Labs, SITE Centers, IGM Biosciences, ATIF Holdings, Arqit Quantum781OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 07.45 A.M. ET).In the Green SITE Centers Corp. (SITC) is up over 53% at $18.12. ATIF...
► Artikel lesen
01.10.24Shattuck Labs, Inc.: Shattuck Labs Provides Company Update and Announces SL-325, a First-In-Class Death Receptor 3 (DR3) Antagonist Targeting the TL1A/DR3 Signaling Pathway107- Interim clinical data for SL-172154 in combination with azacitidine in TP53 mutant (TP53m) acute myeloid leukemia (AML) and higher-risk myelodysplastic syndromes (HR-MDS) showed only modest improvement...
► Artikel lesen
14.06.24Shattuck Labs, Inc.: Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53167- Observed 67% Objective Response Rate (ORR) in frontline HR-MDS patients, primarily with TP53 mutations; initial complete remission (CR)/marrow complete remission (mCR) rate of 58% and median overall...
► Artikel lesen
10.06.24Shattuck Labs, Inc.: Shattuck Labs Announces Orphan Drug Designation Granted by the U.S. Food and Drug Administration (FDA) for SL-172154 for the Treatment of Acute Myeloid Leukemia (AML)165AUSTIN, TX and DURHAM, NC, June 10, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (Nasdaq: STTK), a clinical-stage biotechnology company pioneering the development of bifunctional fusion...
► Artikel lesen
Seite:  Weiter >>
21 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1